SCHEDULE: Avoro Capital Advisors Discloses 5.54% Stake in Avidity

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 5.54% beneficial ownership stake in Avidity Biosciences, Inc. common stock.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh (the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of Avidity Biosciences, Inc. (the "Company") common stock.
• The Reporting Persons collectively own 8,515,792 shares of Avidity Biosciences, Inc. common stock.
• This ownership represents 5.54% of the Company's outstanding common stock.
• The reported shares include 3,060,792 shares of Common Stock issuable upon the exercise of pre-funded warrants.
• The percentage is calculated based on 150,675,742 shares of Common Stock outstanding as of October 31, 2025, as reported in the Company's Form 10-Q.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The disclosure of a significant stake by a reputable investment advisor like Avoro Capital Advisors suggests institutional conviction in Avidity Biosciences' long-term potential, which can be reassuring to other investors.

Positives

• A significant institutional investor, Avoro Capital Advisors LLC, and its controlling person, Behzad Aghazadeh, have taken a substantial 5.54% stake in Avidity Biosciences, Inc., signaling confidence in the company's prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance from Avidity Biosciences, Inc. or the reporting persons regarding the company's future operations or financial performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock for investment purposes, without intent to influence control. The disclosure of Avoro Capital Advisors' stake in Avidity Biosciences indicates a notable institutional interest in the biotechnology sector, particularly in companies like Avidity that are developing RNA-based therapies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity, signaling a vote of confidence from a sophisticated investor.

Key Dates

Recommendation

The filing indicates a significant institutional investment in Avidity Biosciences, which is generally a positive indicator of confidence in the company's prospects. However, a Schedule 13G filing alone does not provide sufficient fundamental information (e.g., financial performance, pipeline updates, strategic changes) to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this institutional interest as one data point among a broader analysis of the company's fundamentals and market conditions.

Keywords

Avidity Biosciences, Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology